Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) has announced it will present updated clinical data from its CARLYSLE study at the upcoming American College of Rheumatology (ACR) Convergence 2025, scheduled for October 24-29 in Chicago.

The presentation will focus on obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-cell therapy, in treating patients with severe refractory systemic lupus erythematosus (srSLE). Initial findings demonstrate a favorable safety profile with no dose limiting toxicities, no ICANS, and no Grade ≥2 cytokine release syndrome. The study showed SLEDAI-2K score improvements and clinical benefits across all patients, with three patients achieving complete renal response.

LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which will include updated follow up from the CARLYSLE study in patients with severe refractory systemic lupus erythematosus (srSLE).

Abstract: 2458
Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting autologous chimeric antigen receptor T-cell therapy (CAR T) with a fast off-rate binding domain, in patients with severe, refractory systemic lupus erythematosus (srSLE): preliminary results from the Phase I CARLYSLE study
Session date and time: Tuesday, October 28, 2025; 10:30am - 12:30pm Central Time
Presenting Author: Maria Leandro, MD

Summary: Initial findings from the ongoing CARLYSLE study of obe-cel in srSLE show a manageable safety profile, with no dose limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS) or Grade ≥2 cytokine release syndrome (CRS). SLEDAI-2K score reduction and clinical benefit were observed in all patients. In addition, three patients who had a complete renal response. Updated data will be presented at the conference.

About Autolus Therapeutics plc 
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com. 

Contact:  

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

FAQ

When will Autolus Therapeutics (AUTL) present at ACR Convergence 2025?

Autolus will present on Tuesday, October 28, 2025, from 10:30am to 12:30pm Central Time at ACR Convergence 2025 in Chicago.

What are the initial results of Autolus' CARLYSLE study for lupus treatment?

Initial results showed a manageable safety profile with no dose limiting toxicities, improved SLEDAI-2K scores, clinical benefits in all patients, and complete renal response in three patients.

What is obe-cel and how is it being used in Autolus' lupus study?

Obe-cel is a CD19-targeting autologous CAR T-cell therapy with a fast off-rate binding domain, being studied in patients with severe, refractory systemic lupus erythematosus (srSLE).

Who is presenting Autolus' CARLYSLE study results at ACR 2025?

Dr. Maria Leandro will be the presenting author of the CARLYSLE study results at ACR Convergence 2025.